Navigation Links
NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
Date:9/15/2008

PARIS, September 15 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today announced successful top-line results from the second phase 3 study for naproxcinod in 1020 patients with osteoarthritis of the knee (the 302 study). Both doses of naproxcinod (750 mg and 375 mg bid) met the three co-primary efficacy endpoints at week-13 (p<0.001). The study also comfortably met the main secondary endpoint, demonstrating that naproxcinod 750 mg bid was statistically non-inferior to naproxen 500 mg bid on the WOMAC(TM) pain and function subscales at week-13 and 26. Naproxcinod is the first compound in the new Cyclooxygenase-Inhibiting Nitric Oxide-Donator (CINOD) class of anti-inflammatory agents, which NicOx is developing as a drug for the treatment of the signs and symptoms of osteoarthritis.

NicOx' phase 3 clinical program for naproxcinod consists of three pivotal trials (including the previously completed 301 study in osteoarthritis of the knee and the ongoing 303 study in osteoarthritis of the hip, in addition to the 302 study). Overall, the results of the 302 study support naproxcinod's non-detrimental effect on blood pressure and are consistent with those observed in the 301 study, with naproxcinod 750 mg bid showing a numerical reduction in systolic and diastolic blood pressure at week-13 and 26, compared to baseline and naproxen 500 mg bid. Existing non-steroidal anti-inflammatory agents (NSAIDs) such as ibuprofen and naproxen have the tendency to raise blood pressure, which is a side effect of particular concern in the osteoarthritis population.

A post hoc pooled analysis of the blood pressure data from the 301 and 302 studies showed a statistically significant reduction for naproxcinod 750 mg bid, compared to naproxen 500 mg bid, in terms of the mean change from baseline at week-13, of 2.3 mmHg (p=0.004) for systolic blood pressure and 1.1 mmHg (p=0.034) for diastolic blood pressure. In the planning of the phase 3 program, NicOx had fo
'/>"/>

SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension
2. NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients
3. NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
4. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
5. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
6. Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
7. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
8. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
9. NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020
10. NicOx Naproxcinod Phase 3 Results Presented at American College of Rheumatology
11. NicOx Naproxcinod ABPM Data Presented at American Heart Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients ... to a recent online survey* sponsored by Mission Pharmacal ... the National Osteoporosis Foundation online support community, revealed that ... medication that comes in a form other than a ...
(Date:1/15/2014)... N.J. , Jan. 15, 2014  Celsion Corporation (the "Company") ... has received commitments from institutional investors to purchase an ... stock in an at-the-market registered direct offering, led by ... entered into definitive purchase agreements with these investors pursuant ...
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and distributors ... able to protect their most important business assets, ... ) Because of the highly-competitive ... remains one of the most litigious industry sectors ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that ... BioMarin, will present a company update at the Citi Global ... 2011 at 8:00 a.m. ET.   Interested parties ... via the investor section of the BioMarin website, www.BMRN.com ...
... Mich., Feb. 22, 2011 Perrigo Company (Nasdaq: ... filed an Abbreviated New Drug Application for calcipotriene 0.005% ... Taclonex® Ointment. Another generic company is the first to ... Betamethasone) ointment is indicated for the topical treatment of ...
Cached Medicine Technology:BioMarin to Present at the Citi Global Healthcare Conference 2Perrigo Confirms Filing for Generic Version of Taclonex® Ointment and Announcement of Lawsuit by Leo Pharma 2Perrigo Confirms Filing for Generic Version of Taclonex® Ointment and Announcement of Lawsuit by Leo Pharma 3
(Date:7/11/2014)... Cancer researchers in Slovenia say genetic variations ... how patients respond to treatment with pemetrexed (Alimta), the ... the full story. Click here to read the ... of Ljubljana and the Ljubljana Institute of Oncology tested ... of polymorphisms. They found that patients with genetic variations ...
(Date:7/11/2014)... 11, 2014 Anterior Cruciate Ligament (ACL) ... the type of material used to create a new ... game, say researchers presenting their work today at the ... Medicine ( AOSSM ). , “Our study ... (tissue harvested from a donor) fail more frequently than ...
(Date:7/11/2014)... Woodland Hills permanent teeth in one day ... Institute in Woodland Hills and Oxnard, Calif., will speak next ... Rey, Calif. , The award-winning prosthodontist, international speaker and ... in one day dental procedure at 1:30 p.m. Friday, July ... 15 years ago, Dr. Jivraj said. Getting new teeth in ...
(Date:7/11/2014)... 11, 2014 BellasDress, the experienced dressmaker ... popular online suppliers when it comes to beach ... new collection of beach wedding outfits in its online ... of elegant outfits. , BellasDress has been considered ... world. According to the company’s senior spokesman, BellasDress provides ...
(Date:7/11/2014)... The International Concussion Organization is ... Best Buy Theater in Times Square, New York ... growing concussion epidemic that is plaguing athletes in ... competition. , The Symposium gathers more than a ... professional athletes and legal scholars for engaging and ...
Breaking Medicine News(10 mins):Health News:New Research Finds Genetic Variables Impact Chemotherapy Response, According to Surviving Mesothelioma 2Health News:ACL Reconstructions May Last Longer With Autografts 2Health News:Woodland Hills Dental Expert Speaking at Nobel Biocare World Symposium in One Week 2Health News:Woodland Hills Dental Expert Speaking at Nobel Biocare World Symposium in One Week 3Health News:Woodland Hills Dental Expert Speaking at Nobel Biocare World Symposium in One Week 4Health News:Woodland Hills Dental Expert Speaking at Nobel Biocare World Symposium in One Week 5Health News:BellasDress Emerges As Popular Online Supplier Of 2014 Beach Wedding Dresses 2Health News:The International Concussion Organization 501(c)(3) hosts its 1st Annual Concussion Symposium at the Best Buy Theater in Time Square, NYC, July 17th, 2014. 2
... statistically significant decline in prostate specific antigen (PSA) levels, ... issue of the Journal of the National Cancer ... was associated with a reduction in prostate cancer risk. ... examined the association between statins and PSA level. ...
... PAUL, Minn., Oct. 28 Dean Barkley,candidate for US Senate ... to fight HIV/AIDS in the US and around the world., ... candidates from,Minnesota will also agree to sign the pledge," said ... "The pledge helps,voters see who is prepared to take a ...
... (Nasdaq: AHII ) announced today that the Company ... quarter ended,September 30, 2008 on Tuesday, November 4, 2008. ... same day at 10:00 a.m.,Eastern Standard Time to discuss ... access the conference call by dialing (719) 785-1758.,Participants will ...
... drug delayed disease progression, researchers found , , WEDNESDAY, Oct. ... to treat erectile dysfunction, appears effective in treating pulmonary ... high blood pressure in the arteries that supply the ... can become tired, dizzy and short of breath, because ...
... INDIANAPOLIS, Oct. 28 WellPoint, Inc. (NYSE:,WLP) announced ... at the,following conferences:, -- Oppenheimer 19th Annual ... Eastern Standard Time ("EST"); and, -- 2008 ... at,9:30 a.m. Mountain Standard Time (11:30 a.m. EST)., ...
... Corporation,(NYSE: DHR ) announced that Executive Vice ... be presenting at the Goldman Sachs Global,Industrials Conference ... 2008 at,8:00 a.m. EST. The audio will be ... Corporation is a leading manufacturer of Professional,Instrumentation, Medical ...
Cached Medicine News:Health News:Statin use associated with reduction in prostate specific antigen levels 2Health News:Senator Dean Barkley Pledges Action on HIV/AIDS Epidemic 2Health News:Cialis May Help Ease Pulmonary Hypertension 2Health News:WellPoint Announces Appearances at Upcoming Conferences 2
Supplied sterile in peel-open packages. Intended for one-time use....
... Used for catheter ... endourology procedures. Increased inner ... coils allows utilization of ... mandril while maintaining tip ...
Supplied sterile in peel-open packages. Intended for one-time use....
... access wire into the renal pelvis through a ... The mandril type shaft construction provides rigidity which ... (0.89 mm) diameter wire guide. The distal portion ... construction over the tapered mandril which provides tip ...
Medicine Products: